This surge may be attributed to the FDA mandating manufacturers of incretin-based medications to revise their product labels in 2009, providing information regarding the potential risk of pancreatitis (Nelson et al., 2014)
Volume Matters Because GLP-1s slow gastric emptying, high-volume snacks (large smoothies, big salads, bulky protein bars) can sit in your stomach for hours causing discomfort
If enough Part D plans opt-in, this model will become the standard beginning January 2027
I feel great, and am beginning a maintenance dose for a while
For many patients, that shift alone changes everything
This could indicate pancreatitis, a rare but serious potential complication of GLP-1 receptor agonists